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Leptin Regulates Bone Formation
via the Sympathetic Nervous System
et al., 1993) suggested a hypothesis whereby bone
mass, body weight, and reproduction would be con-
trolled by the same hormone(s). Testing this hypothesis
Shu Takeda,1,7 Florent Elefteriou,1,7
Regis Levasseur,1 Xiuyun Liu,1 Liping Zhao,5
Keith L. Parker,5 Dawna Armstrong,3
Patricia Ducy,1,2,4 and Gerard Karsenty1,2,6 revealed that leptin, a hormone regulating body weight
and gonadal function, is also a powerful inhibitor of bone1Department of Molecular and Human Genetics
2 Bone Disease Program of Texas formation, i.e., an antiosteogenic factor (Ducy et al.,
2000). Leptin-deficient (ob/ob), leptin receptor-deficient,3 Department of Pathology
4 Department of Medicine and lipodystrophic mice that have in common de-
creased leptin signaling have the same high bone massBaylor College of Medicine
One Baylor Plaza (HBM) phenotype. That these three mutant mouse
strains, characterized by a great disparity in bodyHouston, Texas 77030
5 Department of Internal Medicine weight, displayed the same bone phenotype demon-
strated that it is leptin signaling, not body weight, thatUniversity of Texas Southwestern Medical Center
at Dallas controls bone mass. Infusion of leptin into the third ven-
tricle (ICV) of ob/ob or wild-type (wt) mice decreased5323 Harry Hines Boulevard
Dallas, Texas 75390 bone mass and bone formation parameters, establishing
the existence of a central component in the control of
bone formation (Ducy et al., 2000). These results are in
agreement with the initial hypothesis since obese peopleSummary
that are protected from osteoporosis are resistant to
leptin central action (Ahima and Flier, 2000). The impor-We previously showed that leptin inhibits bone forma-
tance of leptin antiosteogenic function is underscoredtion by an undefined mechanism. Here, we show that
by the fact that leptin deficiency is the only known condi-hypothalamic leptin-dependent antiosteogenic and
tion resulting in the coexistence of HBM and hypogo-anorexigenic networks differ, and that the peripheral
nadism, a condition that otherwise favors bone loss.mediators of leptin antiosteogenic function appear to
Much progress has been made in identifying mecha-be neuronal. Neuropeptides mediating leptin anorexi-
nisms whereby leptin exerts its anorexigenic function.genic function do not affect bone formation. Leptin
Chemical lesioning, molecular elucidation of mouse mu-deficiency results in low sympathetic tone, and genetic
tant strains, and generation of neuropeptide-deficientor pharmacological ablation of adrenergic signaling
mice have identified hypothalamic neurons synthesizingleads to a leptin-resistant high bone mass. -adrener-
orexigenic or anorexigenic molecules that are targetsgic receptors on osteoblasts regulate their prolifera-
of leptin anorexigenic action (Elias et al., 1999; Cowleytion, and a-adrenergic agonist decreases bone mass
et al., 2001; DeFalco et al., 2001). In contrast, the cellularin leptin-deficient and wild-type mice while a -adren-
and molecular bases of leptin antiosteogenic functionergic antagonist increases bone mass in wild-type and
remain unknown. We do not know which hypothalamicovariectomized mice. None of these manipulations af-
areas and networks are targeted by this function of lep-fects body weight. This study demonstrates a leptin-
tin, or if the same neuropeptides mediate anorexigenicdependent neuronal regulation of bone formation with
and antiosteogenic functions of leptin. We further dopotential therapeutic implications for osteoporosis.
not know either the nature (i.e., humoral or neuronal) or
the identity of the mediator(s) emanating from the brainIntroduction
and controlling bone formation. These questions are of
paramount importance from a biomedical viewpoint asIn vertebrates, bone mass is maintained constant
their answers may lead to the generation of drugs en-through the interplay of two functions: bone resorption
hancing bone formation, possibly without affecting bodyby osteoclasts and bone formation by osteoblasts. The
weight. Such drugs are in great demand to treat osteo-concerted action of these two cell types defines bone
porosis.remodeling. The fact that osteoporosis, the most fre-
To decipher the bases of leptin antiosteogenic func-quent bone remodeling disease, is also the most fre-
tion, we used chemical lesioning, genetic, physiological,quent degenerative disease in developed countries
and molecular analyses. Our studies suggest that the(Cooper and Melton, 1996) explains why identifying mo-
anorexigenic and antiosteogenic modes of leptin actionlecular regulators of bone remodeling is such an impor-
are distinct, identify a neuronal regulation of bone forma-tant question of bone biology.
tion, and point toward a therapeutically useful way ofThe precision of the recovery following inducible os-
manipulating this pathway.teoblast ablation in adult mice led us to postulate the
existence of a systemic control of bone formation (Corral
et al., 1998). The high incidence of osteoporosis follow- Results
ing gonadal failure (Riggs et al., 1998) and its low inci-
dence in obese people (Felson et al., 1993; Tremollieres Identification of Hypothalamic
Antiosteogenic Areas
The mediobasal hypothalamus has previously been6 Correspondence: karsenty@bcm.tmc.edu
7 These authors contributed equally to this work. shown to be a critical target of leptin action (Tartaglia et
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Figure 1. Dissociation of Leptin Anorexigenic and Antiosteogenic Actions in the Hypothalamus
(A–C) MSG lesion.
(A) Effect on hypothalamic structure. Cresyl violet staining (top) immunohistochemistry for NPY (middle) and SF1 (bottom). The arcuate nuclei
(ARC) and the VMH are encircled by black and red dotted lines, respectively. The planes of brain sections are located 1.7 from bregma
according to Paxinos’ reference atlas (Franklin and Paxinos, 1997). MSG treatment markedly affected ARC structure and NPY expression
(arrows), while VMH structure and SF1-expressing neurons were preserved.
(B) Histological analysis of vertebrae of MSG-lesioned mice; bone volume (% bone vol./tissue volume) is not affected.
(C) Leptin ICV infusion does not affect body weight (left) but decreases bone volume (right) in MSG-lesioned ob/ob mice (MSGleptin).
(D–F) GTG lesion.
(D) Effect on hypothalamic structure. Cresyl violet staining (top) immunohistochemistry for SF1 (middle) and NPY (bottom). GTG treatment
affected the VMH, resulting in a dense scar and markedly altering the distribution of SF-1-expressiong neurons while preserving ARC structure
and NPY expression.
(E) Histological analysis of vertebrae of GTG-lesioned mice; bone volume and bone formation rate (BFR/BS) are increased.
(F) Leptin ICV infusion decreases body weight (left) but does not affect bone volume (right) in GTG-treated animals (GTGleptin). Asterisks
indicate statistically significant differences between experimental and control groups (p  0.01).
al., 1995; Fei et al., 1997). Two nuclei in this hypothalamic in mediating leptin anorexigenic function. The role of
neurons of these nuclei in mediating leptin antiosteoge-region, the ventromedial hypothalamic nucleus (VMH)
and arcuate nucleus (ARC), have the highest density of nic function was first assessed by chemical lesioning
followed by leptin ICV infusion.neurons expressing ObRb, the signal-transducing form
of the leptin receptor, and both nuclei play a critical role We first treated newborn pups with monosodium glu-
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tamate (MSG), which damages circumventricular neu- pathways without, however, defining precisely their neu-
rons expressing the glutamate receptor (Olney, 1969). roanatomical locations.
As shown by histology, MSG treatment predominantly
affected ARC structures (Figure 1A and see Supplemen-
tal Figures S1 and S2 at http://www.cell.com/cgi/ Leptin Antiosteogenic Function Does Not Require
content/full/111/3/305/DC1). This was illustrated by the Known Anorexigenic Neuropeptides
near absence of neurons synthesizing neuropeptide Y To refine our results from chemical lesions, we used a
(NPY) (Figure 1A). In contrast, immunohistochemical genetic approach. It has been demonstrated that bind-
studies using an antibody against steroidogenic factor ing of -melanocyte-stimulating hormone (MSH), pro-
1 (SF1), a marker of VMH neurons (Ikeda et al., 1995; duced by ARC neurons, to neurons expressing melano-
Dellovade et al., 2000), indicated that the majority of cortin 4 receptor (MC4-R) and melanocortin 3 receptor
these neurons were unaffected by MSG treatment. No (MC3-R) is required for leptin anorexigenic function
lesions outside the hypothalamus could be observed in (Huszar et al., 1997; Vaisse et al., 1998; Yeo et al., 1998;
any of the animals treated. 12-week-old MSG-treated Cowley et al., 2001). To assess the role of melanocortin
mice had a normal bone mass as determined histologi- signaling in leptin antiosteogenic function, we analyzed
cally by measurement of their bone volume (Figure 1B). mutant mouse strains with disrupted melanocortin sig-
To further evaluate the role of MSG-sensitive neurons naling and ob/ob mice treated with a melanocortin re-
in leptin antiosteogenic function, we performed leptin ceptor agonist.
ICV infusion in ob/ob mice treated with MSG. MSG treat-
Ay/a mice have decreased melanocortin signaling due
ment blocked the ability of leptin ICV infusion to de-
to the binding to melanocortin receptors of the agouti
crease body weight but not to decrease bone mass
protein, a competitive antagonist of melanocortin recep-(Figure 1C). The normal bone mass of MSG-treated mice
tor signaling with a high affinity for MC4-R (Miller et al.,along with the decrease in bone mass following leptin
1993; Lu et al., 1994; Fan et al., 1997). As a result, Ay/aICV infusion despite MSG-induced lesions in ob/ob mice
mice develop a late-onset obesity accompanied by aindicates that although leptin anorexigenic function re-
central resistance to leptin anorexigenic function (Ha-quired their presence, its antiosteogenic action can take
laas et al., 1997) that resembles the phenotype observedplace when MSG-sensitive neurons are absent.
in Mc4-r-deficient mice (Huszar et al., 1997). In contrast,Next we treated 4-week-old wt mice with gold thioglu-
multiple lines of evidence indicate that leptin antios-cose (GTG), a compound that destroys glucose-sensi-
teogenic function does take place when melanocortintive neurons (Debons et al., 1962). In each mouse ana-
signaling is disrupted. First, Ay/a mice have a normallyzed, the deleterious effect of GTG treatment was
bone mass (Ducy et al., 2000). Second, Ay/a mice arerevealed by a dense scar distorting the anatomy of the
not resistant to leptin antiosteogenic function, as long-ventral hypothalamus, resulting in a collapse of the third
term ICV leptin infusion decreased bone volume compa-ventricle (Figure 1D and see Supplemental Figures S3
rably in Ay/a mice and wt mice, secondary to a decreaseand S4 at http://www.cell.com/cgi/content/full/111/3/
in the bone formation rate (Figure 2A). Third, Mc4-r-305/DC1). Immunohistochemical studies and cell counting
deficient mice have a normal bone mass (Figure 2B).in GTG-treated mice showed a marked decrease of neu-
rons expressing SF1, whereas NPY-expressing neurons Fourth, ICV infusion of MTII, a MC4-R/MC3-R agonist
were largely but not entirely spared (Figure 1D). Bone (Fan et al., 1997) in ob/ob mice, did not affect their bone
histological analysis revealed that 12-week-old GTG- mass while it significantly decreased their body weight
treated mice displayed a HBM phenotype whose sever- (Figures 2C and 2D).
ity was nearly identical to that of ob/ob mice (Figure 1E). Another anorexigenic polypeptide whose expression
As with ob/ob mice, this HBM was due to an increase is regulated by leptin is cocaine amphetamine related
in bone formation defined by an increase in the bone transcript (CART) (Kristensen et al., 1998). Although
formation rate (Figure 1E). Urinary elimination of deoxy- CART regulates body weight in mice (Asnicar et al.,
pyridinoline (dpd), a collagen breakdown product indic- 2001), Cart-deficient mice did not display HBM (data
ative of osteoclast activity, and osteoclast numbers not shown). Taken together, these experiments indicate
were normal, indicating that bone resorption was not that melanocortin- and CART-signaling pathways, which
overtly affected by GTG treatment (data not shown). are critical for leptin anorexigenic action, are not re-
These findings established that neurons sensitive to quired for its antiosteogenic function. These results are
GTG are involved in the control of bone formation.
consistent with the observation that MSG-sensitive neu-
To determine whether GTG-sensitive neurons were
rons, which are the main hypothalamic source of MSH,implicated in leptin antiosteogenic function, we per-
are dispensable for leptin antiosteogenic action.formed leptin ICV infusion in GTG-treated ob/ob mice.
The analysis of Mc4-r-deficient mice addressed an-Leptin ICV infusion decreased the body weight of these
other concern that could not be studied in mice deficientanimals, indicating that it was effective (Figure 1F). How-
in leptin signaling. The HBM observed in absence ofever and despite the extreme sensitivity of ob/ob mice
leptin signaling raised the possibility that it could beto leptin, its ICV infusion failed to decrease their bone
secondary to coexisting hyperinsulinism. The normalmass (Figure 1F). These data indicate that GTG-sensitive
bone mass in Mc4-r-deficient mice despite their ele-neuronal networks are necessary for leptin antiosteoge-
vated plasma insulin levels argues that hyperinsulinismnic function. The observation that GTG or MSG treat-
does not lead to HBM (Table 1). Three other lines ofment affected differentially leptin antiosteogenic and
evidence presented below further dissociate plasma in-anorexigenic functions suggests that these two func-
tions are executed, at least partly, by distinct neuronal sulin levels and bone mass regulation.
Cell
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Figure 2. Anorexigenic Neuropeptides Do Not Control Bone Formation
(A) Histological analysis of vertebrae of 4-month-old agouti yellow mutant mice (Ay/a) infused ICV with PBS or leptin. ICV leptin infusion causes
a decrease in bone volume (Bone vol. %) and bone formation rate (BFR/BS).
(B) Histological analysis of vertebrae of 3-month-old Mc4-R-deficient mice (MC4-R/); bone volume is normal.
(C and D) Histological analysis of vertebrae of ob/ob mice infused ICV with PBS or MTII; bone volume is not affected (C), whereas body weight
is decreased (D). Asterisks indicate statistically significant differences between experimental and control groups (p 0.01). Error bars represent
SEM.
Peripheral Mediation of Leptin shown). Four weeks later, the animals were sacrificed
and analyzed. As expected, bone mass dropped signifi-Antiosteogenic Function
cantly in the ob/ob mouse receiving leptin ICV; in con-We next asked whether the signal(s) emanating from
trast, we never observed any modification of bone massthe hypothalamic antiosteogenic network was/were of
in the contralateral mouse (Figure 3A). Although it doeshumoral or of neuronal nature. To that end we relied
not rule out the existence of a short-lived humoral medi-on crosscirculation (parabiosis) experiments between
ator, this experiment raised the possibility of a neuronalob/ob animals (that have no circulating leptin). Parabio-
mediation of leptin antiosteogenic function.sis experiments were performed as described in Experi-
None of the experiments presented above excludedmental Procedures and dye injection confirmed effective
the possibility that leptin could also affect osteoblastcrosscirculation with 95% equilibrium between the
function by acting locally. To test this hypothesis, twoparabiotic animals after 2 hr. Two weeks after parabio-
transgenic mouse lines were generated that use thesis, we implanted in one mouse of each parabiosed pair
osteoblast-specific fragment of the 1(I) collagen pro-a pump infusing leptin ICV. The absence of measurable
moter (Rossert et al., 1995) to drive Leptin expressionleptin in serum of all the animals analyzed ruled out a
in osteoblasts [1(I)–leptin] (Figure 3B). Northern blotleakage of leptin into the general circulation (data not
analysis and immunocytochemistry demonstrated a
high level of leptin synthesis by osteoblasts (Figures 3B
and 3C) that resulted in a slight increase in plasma leptinTable 1. Serum Insulin Levels and Bone Mass
level although it remained within the normal range (wt,
Insulin (ng/ml) Bone Volume
3.2  0.4 ng/ml versus 1(I) leptin, 5.6  0.8 ng/ml, n 
Wild-type 0.8  0.3 Normal 7 per genotype). The bioactivity of leptin transcribed by
MC4-R/ 23.0  6.0a Normal this transgene was established by showing that follow-
Dbh/ 1.0  0.4 High ing DNA transfection leptin increased the activity of a
ob/ob 19.6  0.8 High
Stat3-dependent luciferase reporter construct in 293ob/obisoproterenol 4.4  0.4 Low
cells expressing ObRb (Figure 3D). Despite this highWild-typepropranolol 0.8  0.1 High
local level of bioactive leptin, the bone mass of the
a Huszar et al., 1997
transgenic mice was indistinguishable from that of wt
Neuronal Mediation of Leptin Antiosteogenic Action
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Figure 3. Peripheral Mediation of Leptin Anti-
osteogenic Function
(A) Histological analysis of vertebrae of para-
biosed ob/ob mice subsequently infused with
PBS or leptin. Leptin ICV infusion decreases
the bone volume (Bone vol. %) of the ipsilat-
eral mouse (Leptin), but not in the contralat-
eral mouse (Leptin partner). No effect was
observed with PBS (PBS and PBS partner).
(B) Generation of osteoblast-specific leptin
(1(I)-leptin) transgenic mice. Top: schematic
representation of the construct. The mouse
leptin cDNA is under the control of the 2.3
kb osteoblast-specific fragment of the 1(I)
collagen promoter. Bottom: Northern blot
analysis of the transgene expression in bone.
(C) Leptin immunoreactivity is detectable in
bones of 1(I)-leptin mice but not of wt mice.
(D) Bioactivity analysis of the 1-leptin trans-
gene performed in 293 cells expressing ObRb
cotransfected with the 1(I)-leptin transgene
and a Stat3-dependent promoter-luc con-
struct.
(E) Histological analysis of vertebrae of 12-
month-old 1(I)-leptin transgenic mice. Lep-
tin expression in osteoblasts does not affect
bone volume. Asterisks indicate statistically
significant differences between experimental
and control groups (p 0.01). Error bars rep-
resent SEM.
mice at any age including 1 year (Figure 3E). This result et al., 1999; Bliziotes et al., 2000). This HBM was second-
ary to an increase in the bone formation rate and in theindicates that the primary basis of leptin antiosteogenic
function is not a direct action on osteoblasts. number of osteoblasts while markers of bone resorption
were normal (Figures 4A–4D and data not shown). The
HBM observed in Dbh-deficient mice was not associ-Sympathetic Regulation of Bone Formation
ated with hyperinsulinism or with other hormonal pertur-A well-characterized consequence of leptin deficiency
bations besides a high corticosterone level (Table 1 andis a reduced activity of the sympathetic nervous system
data not shown). Catecholamines are released from two(SNS) (Bray and York, 1998). Moreover, it has been pro-
main sources: the sympathetic nerves and the adrenalposed that the VMH mediates leptin-induced increase
glands. To determine whether the adrenal productionin catecholamine secretion (Ruffin and Nicolaidis, 1999;
of catecholamines is involved in the regulation of boneSatoh et al., 1999). These observations as well as our
mass, we analyzed wt mice in which the adrenal medulla,own findings led us to explore the role of the SNS in the
the main source of circulating epinephrine (Young andcontrol of bone formation.
Landsberg, 1998), had been surgically removed 4 weeksAs SNS function is mediated through adrenergic re-
previously. Histological analysis showed that removalceptors, we studied mutant mice deficient in dopamine
of the adrenal medulla did not affect bone mass (Figure-hydroxylase (DBH), an enzyme necessary to produce
4E). These results establish the existence of a neuronalnorepinephrine and epinephrine, the catecholamine li-
regulation of bone formation.gands for adrenergic receptors. Histological examina-
We next asked whether there was a direct link be-tion revealed the existence of a HBM in Dbh-deficient
tween leptin central antiosteogenic function and themice, albeit less severe than the one observed in ob/ob
SNS regulation of bone formation. To that end we per-mice (Figure 4A). This finding was significant since Dbh-
formed leptin ICV infusion in Dbh-deficient mice. Thisdeficient mice have an increase in serum corticosterone
infusion led to a near disappearance of the gonadal fatand in dopamine levels (Alaniz et al., 1999), two condi-
tions favoring low bone mass (Adachi et al., 1993; Alaniz pad in all Dbh-deficient mice treated, indicating that
Cell
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Figure 4. Sympathetic Control of Bone Formation
(A) Histological analysis of vertebrae of 12-month-old Dbh-deficient mice (Dbh/). Bone volume (Bone vol. %) is significantly increased in
Dbh/ mice.
(B) Calcein double labeling, bone formation rate (BFR/BS, white arrows), and number of osteoblasts (N.Ob/B.Pm) are increased in Dbh/
mice.
(C and D) Normal osteoclast number (N.Oc/B.Pm) and deoxypyridinoline crosslinks elimination in Dbh-deficient mice.
(E) Histological analysis of vertebrae of adrenal medullectomized mice (ADX); bone volume is not affected.
(F and G) Leptin icv infusion in Dbh/ mice. Fat pad weight is decreased (F) while bone volume is not affected (G) by the treatment. Asterisks
indicate statistically significant differences between experimental and control groups (p  0.01). Error bars represent SEM.
centrally delivered leptin can affect body weight reg- tures (Figure 5A). Immunohistochemical analysis of long
bones from transgenic mice expressing LacZ under theulation in the absence of norepinephrine and epineph-
control of the osteoblast-specific fragment of the 1(I)rine (Figure 4F). Strikingly, leptin failed to decrease the
collagen promoter verified the presence of 2-adrener-bone mass of Dbh-deficient mice (Figure 4G), demon-
gic receptors on osteoblasts (Figure 5B). No other ad-strating that leptin antiosteogenic function requires a
renergic receptor subtype could be detected. Moreover,functional SNS.
axons immunoreactive with anti-neurofilament and anti-
tyrosine hydroxylase antibodies were observed in the
Functional Adrenergic Receptors on Osteoblasts vicinity of osteoblasts (Figures 5C and 5D). Electron
For a sympathetic regulation of bone formation to exist, micrographs confirmed the presence of unmyelinated
several requirements have to be fulfilled. The first one peripheral nerve axons coursing through the marrow
is that functional adrenergic receptors must be present adjacent to bone trabeculae and to osteoblasts (Figure
on osteoblasts. Gene expression analysis by RT-PCR 5E). -adrenergic receptors are G-coupled receptors
and Northern blot showed the presence of 2-adrenergic that signal through the cAMP pathway (Benovic et al.,
receptor transcripts, but of no other transcripts for ad- 1988). Thus, to assess the biological relevance of the
presence of 2-adrenergic receptors on osteoblasts, werenergic receptors, in primary mouse osteoblast cul-
Neuronal Mediation of Leptin Antiosteogenic Action
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Figure 5. Presence of Functional Adrenergic Receptors on Osteoblasts
(A) RT-PCR (top) and Northern blot analyses (bottom) of - and -adrenergic receptor expression. Only 2-adrenergic receptor expression
can be detected in osteoblasts. Samples were from primary osteoblasts (ob), heart (C1, C2, C4, and C6), brown adipose tissue (C3), and liver
(C5). Hprt amplification and Gapdh expression were used as controls for loading and RNA integrity.
(B) Immunolocalization of 2-adrenergic receptors in bones of wt mice and transgenic mice overexpressing LacZ in osteoblasts (inset).
Mononucleated cells express 2-adrenergic receptors and those cells are X-gal positive, i.e., osteoblasts.
(C and D) Immunolocalization of neurofilament (C) and tyrosine hydroxylase (D, arrow) adjacent to osteoblasts.
(E) Electron micrographs of bone sections of 2-day-old mice. A nerve (n) is located in close vicinity to osteoblasts (ob) and bone trabeculae (t).
(F) In murine primary osteoblasts (left) and human SaOS-2 osteoblastic cells (right), cAMP production is induced by -adrenergic receptor
agonists (isoproterenol, iso; norepinephrine, NE) and inhibited by the addition of -adrenergic antagonist (propranolol, Pro). PTH was used
as a positive control.
treated these cells with isoproterenol, a -adrenergic resorption parameters were unaffected (data not shown).
Identical results were obtained when using 10 mg/kg/agonist, alone or in the presence of propranolol, a
-adrenergic receptor antagonist; with norepinephrine, day of isoproterenol (data not shown). Two aspects of
this experiment are of particular importance. First, thisthe natural ligand of -adrenergic receptors; with phen-
ylephrine, an -adrenergic agonist; or with vehicle and low bone mass developed while ob/ob mice remained
hyperinsulinemic, further dissociating hyperinsulinismmeasured cAMP production. As a positive control we
used parathyroid hormone (PTH), which binds to another and bone mass regulation (Table 1). Second, at these
two doses, isoproterenol decreased bone mass withoutG-coupled receptor present in osteoblasts (Gardella and
Juppner, 2001). Isoproterenol or norepinephrine but not affecting body weight, demonstrating the existence of a
range of doses in which isoproterenol affects selectivelyphenylephrine treatment increased cAMP production to
a similar extent as PTH. These effects were abolished by bone mass (Figures 6A and 6C). To determine the role
of the SNS in animals that have none of the metabolicpropranolol treatment. The same results were obtained
using mouse and human osteoblasts (Figure 5F). and neurological abnormalities caused by leptin defi-
ciency, we repeated this experiment in wt mice. Isopro-
terenol again significantly decreased bone mass, boneDecreased Bone Mass but Persistent Obesity in
Sympathomimetic-Treated ob/ob Mice formation rate, and osteoblast number without affecting
their body weight (Figures 6D–6F). The increased ex-A second requirement is that treatment of ob/ob mice
with sympathomimetic agents should decrease their pression of uncoupling protein 1 (Ucp1) in brown adi-
pose tissue indicated that isoproterenol mimicked anbone mass. To address this point, 1-month-old ob/ob
mice were treated for 6 weeks with the -adrenergic increase in sympathetic activity in both ob/ob and wt
mice (Figure 6G; Scarpace and Matheny, 1998). Takenagonist isoproterenol or vehicle. As shown in Figure 6A,
long-term isoproterenol treatment (3 mg/kg/day) re- together, these data identify the SNS, acting through 2
adrenergic receptors, as a regulator of bone formationsulted in a massive bone loss in the vertebrae and long
bones of ob/ob mice. This was secondary to a marked independent of the effect it may have on body weight.
To elucidate the bases of the antiosteogenic effect ofdecrease in the bone formation rate and in the number
of osteoblasts per bone perimeter (Figure 6B) while bone isoproterenol in vivo, we studied osteoblast prolif-
Cell
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Figure 6. A -Adrenergic Agonist Inhibits Bone Formation
Isoproterenol (Iso) treatment of ob/ob (A–C) and wt (D–F) mice. (A and D) Histological analysis of vertebrae and tibia (A). Bone volume (Bone
vol. %) is decreased by Iso treatment. (B and E) Calcein double labeling (top), bone formation rate (BFR/BS, white arrows), and osteoblast
number (N.Ob/B.Pm) are decreased by Iso treatment. (C and F) Body weight analysis. These doses of Iso do not affect body weight.
(G) Northern blot analysis. Iso increases UCP-1 expression in brown adipose tissues (top).
(H) Osteoblast proliferation. Immunolocalization of BrdU incorporation (red staining, arrows) in calvariae of Iso, dexamethasone (Dex), or
vehicle (Cont)-treated mice. Percentages of BrdU-positive cells relative to control are indicated on the right.
(I) Northern blot analysis of Cbfa1 and 1(I) collagen expression in primary osteoblasts treated by Iso, Iso and propranolol (IsoPro), or vehicle
(Cont). Gapdh expression was used as an internal control for all Northern blots. Asterisks indicate statistically significant differences between
experimental and control groups (p  0.01).
eration, gene expression, and apoptosis. Following bro- and Annexin-V staining levels and did not observe any
change in isoproterenol-treated versus control osteo-modeoxyuridine (BrdU) labeling in vivo, calvariae of iso-
proterenol-treated wt mice showed a nearly 2-fold blasts (data not shown). These results indicate that the
antiosteogenic function of the SNS is secondary to anreduction in the number of positive cells compared to
calvariae of control mice, indicating that isoproterenol inhibition of osteoblast proliferation and function.
reduces osteoblast proliferation (Figure 6H). As a control
we used dexamethasone, which severely reduced os- A -Adrenergic Antagonist Increases Bone Mass
in Wild-Type and Ovariectomized Miceteoblast proliferation. Osteoblast gene expression stud-
ies revealed that isoproterenol treatment decreased the The most important biomedical requirement for regula-
tion of bone formation by the SNS is that -adrenergicexpression of Cbfa1, a transcription factor controlling
osteoblast function (Ducy et al., 1999), and 1(I) colla- antagonists ( blockers) should increase bone mass by
increasing bone formation. To address this point, wtgen, a gene encoding the main component of the bone
extracellular matrix (Figure 6I). Treatment with proprano- mice were treated for 5 weeks with propranolol (0.4 mg/
day). This treatment resulted in a significant increase inlol, a -adrenergic antagonist, reversed the inhibitory
effect of isoproterenol on gene expression (Figure 6I). bone mass in vertebrae and long bones (Figure 7A). In
some propranolol-treated mice, the bone volumeTo study apoptosis, we looked at Caspase 3 expression
Neuronal Mediation of Leptin Antiosteogenic Action
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Figure 7. A -Adrenergic Antagonist Increases Bone Mass
Propranolol (Pro) treatment of wt (A, C), wt receiving leptin ICV infusion (D, E), ovariectomized (OVX), and sham-operated (Sham OVX) (F and
G) mice. Histological analysis of vertebrae (A, B, E–G) and tibiae (A). Bone volume (Bone vol. %) is increased by Pro treatment (A and F).
Calcein double labeling (top), bone formation rates (BFR/BS, white arrows), and osteoblast numbers (N.Ob/B.Pm) are increased in propranolol-
treated mice (B and G). Body weight (C) is not affected. Leptin ICV infusion decreases fat pad weight but not bone mass in pro-treated wt
mice (D and E). Pro treatment prevents bone loss by increasing bone formation parameters in OVX mice (F and G). Asterisks indicate statistically
significant differences between experimental and control groups (p  0.01). Diamond indicates statistically significant differences between
OVX and sham-operated mice (p  0.01). Error bars represent SEM.
matched what is observed in ob/ob mice. This increase in propranolol-treated mice. Centrally delivered leptin
led to the disappearance of fat pads in propranolol-in bone mass was secondary to an increase of both
the bone formation rate and the number of osteoblasts treated mice but did not affect their bone mass (Figures
7D and 7E). This experiment is a second argument sup-(Figure 7B). The change in bone mass induced by pro-
pranolol occurred while the body weight and fat pad porting the hypothesis that leptin antiosteogenic func-
tion requires sympathetic activity.weight of the animals remained normal (Figure 7C and
data not shown). Propranolol did not cause hyperinsulin- This effect of propranolol on bone formation observed
in wt mice suggested that it might mitigate the osteopo-ism or other hormonal modifications (Table 1 and data
not shown). Next, we asked if there was a link between rosis observed following estrogen depletion. To test if
it was the case, we performed ovariectomy in 6-week-leptin antiosteogenic function and the effect of  block-
ade on bone mass. To that end we infused leptin ICV old wt mice and treated them for 7 weeks with proprano-
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lol or vehicle. Estrogen depletion by ovariectomy de- mus is regulated by leptin (Kristensen et al., 1998). Cart-
deficient mice develop, on a high fat diet, a mild obesitycreased bone mass in vehicle-treated mice. In contrast,
propranolol-treated ovariectomized mice had a normal (Asnicar et al., 2001), yet they do not have HBM. The
ability to differentially modulate the anorexigenic andbone mass (Figure 7F). This preventative effect of pro-
pranolol treatment was due to a striking increase in the the antiosteogenic effect of leptin as observed in MSG-
and GTG-treated mice and in mutant mouse strains sug-bone formation rate and in the osteoblast number that
were both significantly higher than in control ovariecto- gests that these two functions are executed at least in
part by distinct neuronal networks. We remain aware,mized mice (Figure 7G). This latter result underscores
the physiological and therapeutic importance of the however, that a direct demonstration will have to await
a genetic identification of leptin antiosteogenic neuronssympathetic regulation of bone formation.
using cell-specific inactivation of the leptin receptor in
the nervous system.Discussion
We have identified neuronal networks required for leptin Sympathetic Activity and Regulation
of Bone Formationantiosteogenic function and demonstrated that the SNS
is a negative regulator of bone formation. Remarkably, While we were unable to provide evidence showing that
leptin acts locally on osteoblasts or that hyperinsulinismthis inhibitory role of the SNS on bone formation could
be modulated without affecting body weight. Besides explains leptin antiosteogenic function, several lines of
evidence establish that the SNS regulates bone forma-providing a molecular basis for leptin antiosteogenic
function, these findings establish a biochemical basis tion in vivo. These include results of parabiosis experi-
ments, analysis of Dbh-deficient mice, and treatment offor the neuronal regulation of bone remodeling. That a
-adrenergic antagonist could overcome the deleterious ob/ob, wt, or wt ovariectomized mice with sympathetic
agonists or antagonists. In our experiments, the effectseffect of ovariectomy on bone without affecting body
weight has major implications for treatment of osteopo- of the SNS on bone mass are independent of changes
in body or fat mass, a dissociation that has major thera-rosis.
peutic implications. Also of considerable importance is
that the failure of leptin ICV infusion to decrease boneSpecificity of Leptin Antiosteogenic Function
mass in Dbh-deficient and in propranolol-treated miceOur analysis provides additional evidence in favor of a
establishes a direct link between leptin antiosteogeniccritical role played by the hypothalamus in the mediation
function and sympathetic activity.of leptin antiosteogenic function. It also implies, with all
Other observations in mice and rats support the exis-the inherent limitations of chemical lesion studies, that
tence of a sympathetic regulation of bone formation.GTG-sensitive neuronal networks are a target of leptin
For instance, Dopamine transporter-deficient mice, inantiosteogenic action while MSG-sensitive neurons may
which rapid uptake of dopamine into presynaptic termi-be dispensable for this action. We wish to stress, how-
nals does not occur, are osteopenic (Bliziotes et al.,ever, that chemical lesioning studies have limitations
2000). This latter observation suggests that the in-and cannot identify precisely the location of subgroups
creased level of circulating dopamine observed in Dbh-of neurons in the hypothalamus required for leptin anti-
deficient mice (Alaniz et al., 1999) may have limitedosteogenic function. These limitations are inherent to
rather than created or amplified their bone phenotype.the technique and will only be overcome by further stud-
Likewise, the anabolic effect of  blockers on bone for-ies using a series of neuronal subpopulation-specific
mation could account for their beneficial effects in boneinactivations of the leptin receptor in mice. Likewise,
fracture in rats (Minkowitz et al., 1991). Although cross-chemical lesions do not rule out that other neuronal
circulation experiments in parabiosed mice do not ex-populations located elsewhere in the brain may be in-
clude the possibility of a short-lived humoral mediatorvolved in leptin antiosteogenic function provided, how-
of leptin antiosteogenic function, the result of the adre-ever, that they express ObRb, the gene encoding the
nalectomy experiment would argue against such asignal transducing form of the leptin receptor.
mechanism. Furthermore, the low bone mass of panhy-We also used genetically modified mouse strains to
popituitarism patients does not support this notiondetermine whether leptin antiosteogenic and anorexi-
(Kaufman et al., 1992).genic functions were using identical neuronal relays.
One neuropeptide implicated in leptin anorexigenic
function is MSH, which is produced by ARC neurons Leptin as a Master Hormone
The pleiotropic functions of leptin that include controland that binds to the melanocortin receptors. This sig-
naling pathway is disrupted in Ay/a and Mc4-r-deficient of body weight, reproduction, and bone formation are
reminiscent of the many functions of hormones suchmice that do not display any bone mass abnormality.
Moreover, Ay/a mice are not resistant to leptin antios- as cortisol, estrogen, thyroid hormone, and insulin. By
analogy with the notion that master genes orchestrateteogenic function, whereas treatment of ob/ob mice with
a melanocortin receptor agonist decreased their body cell differentiation programs during development, we
propose that leptin along with these other hormonesweight without affecting their bone mass. These results,
indicating that melanocortin agonists are not major reg- defines a group of “master hormones” involved in the
control of several important homeostatic functions. Inulators of bone formation, are consistent with the ab-
sence of an overt effect of MSG-induced damage on particular, the existence of HBM despite an increase
in bone resorption in the absence of leptin signalingleptin antiosteogenic function. CART is another anorexi-
genic neuropeptide whose expression in the hypothala- indicates that control of bone formation is one of the
Neuronal Mediation of Leptin Antiosteogenic Action
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lesioning, 2-day-old C57BL/6J pups were injected daily subcutane-primary functions of leptin. Master hormones may make
ously with either PBS or MSG (2 mg/g) for 10 days.use of different modes of action to achieve their various
functions. Analysis of glucocorticoid receptor mutants
Generation of Transgenic Mice and Molecular Studieshas revealed that cortisol, the hormone binding to this
The 1(I) leptin transgene was generated by cloning the mouse
receptor, uses different pathways to achieve different leptin cDNA downstream of the 2.3 kb osteoblast-specific fragment
functions (Reichardt et al., 1998; Karst et al., 2000). The of the 1(I)collagen promoter. Transgenic founders were generated
by standard techniques (Ausubel, 1995). Genotypes were deter-evidence presented here distinguishing its anorexigenic
mined by PCR. Progenies of two lines expressing the transgeneand antiosteogenic mode of action suggests that the
were analyzed. Northern blot analyses were performed using totalsame may be true in the case of leptin. The ability of
RNA or poly(A) RNA according to standard protocols. RT-PCRmaster hormones to use different pathways to fulfill mul-
analysis of adrenergic receptor expression was performed on ran-
tiple functions in vertebrates may have been one way dom-primed cDNA for 27 cycles. All primer sequences are available




Biomedical Implications Specimens were embedded in paraffin and sectioned at 6 	m.
Brains were stained with 0.1% cresyl violet using standard proce-Does this regulatory pathway operate in humans as well
dures. Immunohistochemistry was performed according to standardas in mice? To date only correlative lines of evidence
protocols (Ausubel, 1995). In vivo osteoblast proliferation assayscan be gathered. One such line of evidence indicates
were performed on newborn mice treated daily for 5 days with 40that a sympathetic regulation of bone mass does exist in
	g isoproterenol, 4 	g dexamethasone, or vehicle. BrdU (0.4 mg)
human and plays an important role. Reflex sympathetic was injected ip at day 5, and mice were sacrificed 2 hr later. BrdU
dystrophy is a human disease characterized by manifes- incorporation was detected by immunohistochemistry using Zymed
BrdU staining kit (Zymed Laboratories, Inc.). Four pups per treat-tations of hyperadrenergic activity including osteoporo-
ment were analyzed and 10 calvariae sections were counted persis. Remarkably, treatment of patients affected by this
animal. NovaRED was used as a chromogenic peroxidase substrate.disease with  blockers corrects most manifestations
Sections were counterstained with hematoxylin.including the osteoporosis (Schwartzman, 2000). The Histological analyses were performed on undecalcified sections
existence of an osteoporosis in a human disorder char- stained by von Kossa and counterstained by von Gieson (Ducy et
acterized by excessive sympathetic activity and the dis- al., 2000). Static and dynamic histomorphometric analyses were
performed according to standard protocols (Parfitt et al., 1987) usingappearance of the osteoporosis with  blockers treat-
the Osteomeasure Analysis System (Osteometrics, Atlanta). Six toment is entirely consistent with our finding in mice and
twelve animals were analyzed for each group. Statistical significancesuggests that additional studies should be performed
was assessed by Student’s t test.in other forms of osteoporosis. Indeed, although many
drugs can effectively stop bone destruction in this dis- Cell Cultures and Bioassays
ease, there is a need for drugs that enhance bone forma- Primary osteoblast cultures were established as previously de-
tion. The observation that propranolol, a widely used scribed (Ducy et al., 2000) and maintained in MEM/0.1 mg/ml
ascorbic acid supplemented with 10% FBS. SaOS-2 were grown indrug with no major deleterious effects, can significantly
MEM/10% FBS. For cAMP assay, confluent cultures were incubatedincrease bone formation and bone mass without affect-
with serum-free medium containing 100 	M IBMX (3-isobutyl-ing body weight provides novel opportunities to design
1-methylxanthine, Sigma) for 8 min before PBS, PTH(1-34) (Bachem),efficient bone-forming drugs. isoproterenol, norepinephrine, phenylephrine (Sigma), or proprano-
lol were added for 5 min. Intracellular cAMP concentration was
measured by immunoassay (R&D Systems). For gene expressionExperimental Procedures
analyses, primary osteoblasts were treated for 72 hr with appro-
priate drugs in 0.1% FBS. Hormone serum levels were quantifiedAnimals, Treatments, and Surgical Procedures
using immunoassay kits from Peninsula Laboratories (Insulin) orWild-type (C57BL/6J) and mutant (C57BL/6J Ay/a, C57BL/6J ob/ob)
Alpco Diagnostics (leptin). Deoxypyridinoline crosslinks and Creati-mice were obtained from the Jackson laboratory and adrenal medul-
nine were measured in morning urines using the Quidel kits. 1(I)lectomized mice from Harlan Tecklad laboratory. Dbh/ mice were
leptin bioactivity was verified by cotransfection of 293 cells express-rescued as previously described (Thomas et al., 1998). Isoproterenol
ing ObRb with a STAT3-responsive-luc reporter construct, pSVgal(Sigma) was injected intraperitoneally (ip) once daily for 6 weeks at
plasmid, and 1(I) leptin expression vector or mock. Twenty-four30 mg/kg (wt) or 3 mg/kg (ob/ob). Propranolol (Sigma) was added
hours later, luciferase and -galactosidase activities were mea-to the drinking water at a concentration of 0.5 g/l. For ICV infusion,
sured. Data represents ratios of luciferase/-galactosidase activi-a 28-gauge cannula (Brain infusion kit II, Alza) was implanted into
ties, and values are mean of six independent transfection experi-the third ventricle as previously described infusing human leptin
ments.(Sigma) at 8 ng/hr or MT-II at 125 ng/hr (Phoenix Pharmaceuticals)
for 28 days (Ducy et al., 2000). The cannula was connected to an
osmotic pump (Alza) placed in the dorsal subcutaneous space of Acknowledgments
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